"Unveiling the Reality of New Alzheimer's Drugs: A Portland Man's Hopeful Trial"

The development of new Alzheimer's drugs, lecanemab and donanemab, has sparked hope for a cure, but their effectiveness and potential side effects are under scrutiny. While these drugs target the amyloid theory and have shown some slowing of disease progression in trials, the overall impact is minimal and comes with significant side effects. The push for routine screening and early treatment raises ethical concerns, and the allocation of public funds for these drugs versus social care is being debated. Critics caution against exaggerated claims and emphasize the need for continued research and caution in the pursuit of a cure for dementia.